JDRF’s T1D Fund: Can Venture Philanthropy Spur Diabetes Device Innovation?


JDRF’s philanthropic venture capital fund is focused on accelerating life-changing solutions to cure, prevent, and treat type 1 diabetes through catalytic commercial investment. It’s a unique solution that Fund Managing Director Katie Ellias believes will help spur innovation and bring new, disease-modifying therapies to patients more quickly.

Since its founding nearly 50 years ago, JDRF, formerly known as the Juvenile Diabetes Research Foundation, has been a staunch advocate for, and supporter of, early-stage research into treatments for type 1 diabetes (T1D).

This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.

Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to MedTech Strategist:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to MedTech Strategist
Subscribe to ELITE Strategist

Become an ELITE Strategist and unlock access to both MedTech Strategist and MTS Market Pathways.

Subscribe to Elite


We're here to help! Please contact us at: